treatment of SE are available, there are no universal treatment guidelines. 4, 5 Differencesalsoexistintermsofdiagnosticcriteriasuchas theapplicationofelectroencephalography [EEG] tomonitorseizure activity, as well as doses and combinations of antiepileptic drugs (AEDs)deliveredtopatientswithSE. [4] [5] [6] This lack of consistent guidance, together with variation in the definitions of SE, complicates a physician's understanding and ability to effectively manage SE. 6 In addition, there is a lack of clinical trial data available for the treatment of refractory SE (RSE) or super-refractory SE (SRSE). 6, 7 Intravenous benzodiazepines, currently the most effective treatment for early SE, act by increasing the frequency of γ-aminobutyric acid A receptor (GABA A R) channel opening and can control SE prior to arrival at an emergency department in up to two-thirds of patients. 7 However, decreased inhibitory signaling through GABA A R, due to internalization of the receptor over the course of SE, results in failure of the mechanisms required for seizure termination and decreased efficacy of benzodiazepines in the later stages of SE. 7, 8 Established SE that does not respond tobenzodiazepinesmaybetreatedwithAEDssuchasphenytoin/ fosphenytoin, valproate, levetiracetam, phenobarbital, and lacosamide. Unfortunately, 31%-43% of patients with established SE will become refractory to first-line AEDs. 3,9-11 RSE is defined as SE that has not responded to first-or second-line therapy, and commonly requires general anesthesia, although many cases are treated without coma induction. 7, 12, 13 SRSE is SE that has continued or recurred despite 24 hours of general anesthesia and has an estimatedmortalityrateof30%-50%. 2, 11 Both RSE and SRSE can cause long-term neurological disability and reduced quality of life compared with those in seizure remission, 2, 11, 14 highlighting the unmet need for novel and effective SE treatments.
Intermsoftheunderlyingpathophysiology,SEmightarisefrom
the decreased inhibitory activity of GABA A R. 15 Additionally, in-
hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor subunits to the synaptic membrane contributes to increased glutamate-mediated excitatory activity and uncontrolled seizures. 8, 15, 16 Therefore, targeting NMDA and AMPA receptors may offer alternative mechanisms to existing treatments for patients with SE. 
| Perampanel treatment
For all patients, the median latency from onset of SE to initiationofperampaneltreatmentwas10days(range,0.5-51;Table2).
The median initial perampanel dose was 6 mg/d (range, 2-24), and perampanel was up-titrated to a median maximum dose of 10 mg/d
(range,4-24),correspondingtoamediandoseof0.15mg/kgbody weight (range, 0.04-0.32). In patients unable to swallow, ground perampanel tablets were administered through a nasogastric tube;
all patients with SRSE (n = 23) received perampanel via this route, as they were typically intubated and/or in an induced coma. Although distributions of mRS scores were similar between perampanel responders and non-responders at admission (P = 0.75), perampanel non-responders demonstrated higher mRS scores at discharge compared with perampanel responders (P = 0.03; Table 1 , Figure 1 ). The mean latency from onset of SE to initiation of perampanel treatment was similar between the two groups (12.7 days vs 12.4 days for perampanel non-responders and responders, respectively; P = 0.61; Table 2 ). Final outcomes were discharged to
| Efficacy outcomes

TA B L E 2 Perampanel treatment parameters and outcomes
All patients (n = 52)
Perampanel responders (n = 19)
Perampanel non-responders (n = 33)
P value (responders vs non-responders)
Treatment parameters
Latency from SE onset to first perampanel administration, d
Mean ( perampanel was initiated at doses of 2 mg 21 and 6 mg. 22 Route of drug administration is another important consideration, in terms of rapid attainment of therapeutic drug levels, and the practicalities of administration while SE is ongoing and patients are potentially under general anesthesia. 3 Nasogastric delivery of F I G U R E 1 mRS scores (A) before admission and SE, and (B) at discharge for patients with SE treated with perampanel. mRS, modified Rankin Scale; SE, status epilepticus perampanel has previously been reported in SE, 20 and intravenous delivery has been achieved in rats. 17, 18 Inourcases,nasogastricde- There are few published cases of perampanel treatment of SE. 20 In a retrospective study of 10 episodes of epilepsia partialis continua or non-convulsive SE, perampanel was considered effective in three or four episodes, dependent on the criteria applied to determine the AED leading to SE cessation. 19 For one of these cases(alsopublishedasacasereport),perampanelwasthefinalAED administered prior to cessation of focal SE, 24 hours after its initial administration. 21 Additionally, a case study documented perampanel administration for treatment of Lance-Adams syndrome, resulting in myoclonic seizure suppression. 28 The case studies presented here provide further support for perampanel as a treatment for RSE.
| Safety outcomes
| D ISCUSS I ON
Previous studies have described varied outcomes with other although a recent phase III trial assessed an experimental treatment (brexanolone,SAGE-547)asathird-linetherapyforSRSE.Whileperampanel is not currently licensed for treatment of SE, the cases described here add to evidence from previous case reports and animal studies that perampanel might be a therapeutic option for treatment of established SE, RSE, and SRSE; this should be confirmed by further research.
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